XT
ANTX icon

XTX Topco’s AN2 Therapeutics ANTX Stock Holding History

XTX Topco’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,402
Closed -$76.6K – 4125
2026
Q1 		$76.6K Buy
+22,402
New +$46.2K ﹤0.01% 3188
2025
Q4 		– Sell
-18,541
Closed -$23.5K – 3286
2025
Q3 		$23.5K Sell
18,541
-7,503
-29% -$8.58K ﹤0.01% 2298
2025
Q2 		$27.6K Buy
+26,044
New +$31K ﹤0.01% 2122
2025
Q1 		– Sell
-34,179
Closed -$47.2K – 2376
2024
Q4 		$47.2K Buy
34,179
+10,520
+44% +$12.8K ﹤0.01% 1902
2024
Q3 		$25.3K Buy
+23,659
New +$41.1K ﹤0.01% 1803
2024
Q2 		– Sell
-38,666
Closed -$126K – 1835
2024
Q1 		$126K Buy
+38,666
New +$421K 0.02% 1313

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

XTX Topco's ANTX Position: Q2 2026 in Review

XTX Topco sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 22,402 shares — an estimated $76.6K sold.

XTX Topco first reported a position in ANTX in Q1 2024 and held it in 6 quarters. The position peaked at $126K in Q1 2024. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • XTX Topco reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 22,402 AN2 Therapeutics shares in Q2 2026, an estimated $76.6K.
  • XTX Topco first reported a position in AN2 Therapeutics in Q1 2024 and held it in 6 quarters.
  • XTX Topco's AN2 Therapeutics position peaked at $126K in Q1 2024.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.